pf-06282999
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2012 (NCT01626976)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- MyeloperoxidaseINHIBITOR
MPO inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O- Mol. weight
- 325.78 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3633460 ↗
Also known as
- 2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2h)-yl)acetamide
- pf-06282999
- pf-06282999
- pf-06282999
- pf-06282999
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01965600 | Phase 1 | Mar 1, 2014 | Pfizer |
| NCT01707082 | Phase 1 | Oct 1, 2012 | Pfizer |
| NCT01626976 | Phase 1 | Jun 1, 2012 | Pfizer |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 3 | 3 | 1 | 2012 |
1 organizations
Page 1 / 1